Note: This section contains information in English only.AstraZeneca's Q2 core earnings rose 18% to $2.63 per share, beating estimates. Strong cancer drug sales helped back its full-year 2026 growth forecast.
Mon, 27 Jul 2026 09:30:06 GMT
Source: Dukascopy Bank SA